E-viri
PDF
Recenzirano
Odprti dostop
-
Johnson, Lisa M; Barrick, Stacey; Hager, Marlies V; McFedries, Amanda; Homan, Edwin A; Rabaglia, Mary E; Keller, Mark P; Attie, Alan D; Saghatelian, Alan; Bisello, Alessandro; Gellman, Samuel H
Journal of the American Chemical Society, 09/2014, Letnik: 136, Številka: 37Journal Article
Glucagon-like peptide-1 (GLP-1) is a natural agonist for GLP-1R, a G protein-coupled receptor (GPCR) on the surface of pancreatic β cells. GLP-1R agoinsts are attractive for treatment of type 2 diabetes, but GLP-1 itself is rapidly degraded by peptidases in vivo. We describe a design strategy for retaining GLP-1-like activity while engendering prolonged activity in vivo, based on strategic replacement of native α residues with conformationally constrained β-amino acid residues. This backbone-modification approach may be useful for developing stabilized analogues of other peptide hormones.
